The FDA has designated Conexxence and Bomyntra as interchangeable biosimilars to the reference products Prolia and Xgeva, ...

The FDA has designated Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.

The U.S. Food and Drug Administration (FDA) has approved two new biosimilars as reference products for Prolia (denosumab) and XGEVA® (denosumab): Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo ...

South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has designated Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) as interchangeable biosimilars to the ...

Merck and Eisai announced termination of a phase III trial of pembrolizumab plus lenvatinib (Lenvima) and transarterial chemoembolization (TACE) for unresectable liver cancer after an interim analysis ...

Amgen posts strong Q3 earnings with soaring drug sales and boosts 2024 outlook. Discover key growth drivers and what sets ...

AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.

Amgen (Nasdaq: AMGN) has reported stronger-than-expected third-quarter results, driven by double-digit gains across several ...

Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025. "We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're ...

Amgen remains a compelling long-term buy, supported by robust R&D investment and a promising drug pipeline for future growth.

Amgen crushed third-quarter expectations late Tuesday, thanks to big sales beats from blockbuster drugs Repatha and Prolia.

An updated edition of the September 01, 2025, article. The global population is aging at an unprecedented pace, fundamentally ...